Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo.

Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS.

Biol Psychiatry. 2010 Nov 1;68(9):854-60. doi: 10.1016/j.biopsych.2010.06.017. Epub 2010 Aug 5.

2.

PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT.

Ding YS, Singhal T, Planeta-Wilson B, Gallezot JD, Nabulsi N, Labaree D, Ropchan J, Henry S, Williams W, Carson RE, Neumeister A, Malison RT.

Synapse. 2010 Jan;64(1):30-8. doi: 10.1002/syn.20696.

3.

Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.

Gallezot JD, Weinzimmer D, Nabulsi N, Lin SF, Fowles K, Sandiego C, McCarthy TJ, Maguire RP, Carson RE, Ding YS.

Neuroimage. 2011 May 1;56(1):268-79. doi: 10.1016/j.neuroimage.2010.09.040. Epub 2010 Sep 30.

4.

Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.

Ding YS, Naganawa M, Gallezot JD, Nabulsi N, Lin SF, Ropchan J, Weinzimmer D, McCarthy TJ, Carson RE, Huang Y, Laruelle M.

Neuroimage. 2014 Feb 1;86:164-71. doi: 10.1016/j.neuroimage.2013.08.001. Epub 2013 Aug 9.

PMID:
23933039
5.

Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine.

Li CS, Potenza MN, Lee DE, Planeta B, Gallezot JD, Labaree D, Henry S, Nabulsi N, Sinha R, Ding YS, Carson RE, Neumeister A.

Neuroimage. 2014 Feb 1;86:306-10. doi: 10.1016/j.neuroimage.2013.10.004. Epub 2013 Oct 10.

6.

A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment.

del Campo N, Fryer TD, Hong YT, Smith R, Brichard L, Acosta-Cabronero J, Chamberlain SR, Tait R, Izquierdo D, Regenthal R, Dowson J, Suckling J, Baron JC, Aigbirhio FI, Robbins TW, Sahakian BJ, Müller U.

Brain. 2013 Nov;136(Pt 11):3252-70. doi: 10.1093/brain/awt263.

7.

Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2.

Sekine M, Arakawa R, Ito H, Okumura M, Sasaki T, Takahashi H, Takano H, Okubo Y, Halldin C, Suhara T.

Psychopharmacology (Berl). 2010 Jun;210(3):331-6. doi: 10.1007/s00213-010-1824-9. Epub 2010 Mar 23.

PMID:
20309528
8.

Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.

Logan J, Wang GJ, Telang F, Fowler JS, Alexoff D, Zabroski J, Jayne M, Hubbard B, King P, Carter P, Shea C, Xu Y, Muench L, Schlyer D, Learned-Coughlin S, Cosson V, Volkow ND, Ding YS.

Nucl Med Biol. 2007 Aug;34(6):667-79. Epub 2007 Jun 8.

PMID:
17707807
9.

Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane.

Spencer TJ, Bonab AA, Dougherty DD, Mirto T, Martin J, Clarke A, Fischman AJ.

J Clin Psychiatry. 2012 Mar;73(3):346-52. doi: 10.4088/JCP.10m06393. Epub 2011 Nov 1.

PMID:
22154896
10.

Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro.

Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, Johnson R, Livni E, Spencer TJ, Bonab AA, Miller GM, Fischman AJ.

J Pharmacol Exp Ther. 2006 Nov;319(2):561-9. Epub 2006 Aug 2.

11.

Age-related changes in prefrontal norepinephrine transporter density: The basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats.

Bradshaw SE, Agster KL, Waterhouse BD, McGaughy JA.

Brain Res. 2016 Jun 15;1641(Pt B):245-57. doi: 10.1016/j.brainres.2016.01.001. Epub 2016 Jan 14.

PMID:
26774596
12.

Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.

Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N.

Am J Psychiatry. 1998 Oct;155(10):1325-31.

PMID:
9766762
14.

Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications.

Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, Ding YS, Gatley SJ, Gifford A, Zhu W, Swanson JM.

Synapse. 2002 Mar 1;43(3):181-7.

PMID:
11793423
15.

Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2).

Takano A, Gulyás B, Varrone A, Maguire RP, Halldin C.

Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1308-14. doi: 10.1007/s00259-009-1118-9. Epub 2009 Mar 20.

PMID:
19300997
16.

Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.

Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, Logan J, Ma Y, Schulz K, Pradhan K, Wong C, Swanson JM.

Arch Gen Psychiatry. 2007 Aug;64(8):932-40.

PMID:
17679638
17.

The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography.

Vanicek T, Spies M, Rami-Mark C, Savli M, Höflich A, Kranz GS, Hahn A, Kutzelnigg A, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Volkow ND, Kasper S, Lanzenberger R.

JAMA Psychiatry. 2014 Dec 1;71(12):1340-9. doi: 10.1001/jamapsychiatry.2014.1226.

18.

Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.

Smith JA, Bourdet DL, Daniels OT, Ding YS, Gallezot JD, Henry S, Kim KH, Kshirsagar S, Martin WJ, Obedencio GP, Stangeland E, Tsuruda PR, Williams W, Carson RE, Patil ST.

Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027. doi: 10.1093/ijnp/pyu027. Erratum in: Int J Neuropsychopharmacol. 2015 Apr;18(6). pii: pyv033. doi: 10.1093/ijnp/pyv033. Patil, D L [corrected to Bourdet, D L].

19.

Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR.

Nyberg S, Jucaite A, Takano A, Kågedal M, Cselényi Z, Halldin C, Farde L.

Int J Neuropsychopharmacol. 2013 Nov;16(10):2235-44. doi: 10.1017/S1461145713000680. Epub 2013 Jul 1.

PMID:
23809226
20.

Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2).

Nogami T, Takano H, Arakawa R, Ichimiya T, Fujiwara H, Kimura Y, Kodaka F, Sasaki T, Takahata K, Suzuki M, Nagashima T, Mori T, Shimada H, Fukuda H, Sekine M, Tateno A, Takahashi H, Ito H, Okubo Y, Suhara T.

Int J Neuropsychopharmacol. 2013 Jun;16(5):937-43. doi: 10.1017/S1461145712001009. Epub 2012 Oct 16.

PMID:
23067569

Supplemental Content

Support Center